Gruenenthal Looks Beyond Pain For Transformative Deals
Executive Summary
Gabriel Baertschi, Gruenenthal’s recently appointed CEO, explains to Mike Ward, global director of content for Informa’s Pharma Intelligence Insights portfolio, how he intends to grow revenues, replenish the pipeline, expand the global footprint and transform the culture of the company.
You may also be interested in...
Grünenthal Taps Into $1bn Surg Sealants Market With Adhesys
German pharma company Grünenthal is expanding its medical device portfolio with the acquisition of surgical adhesives specialist Adhesys Medical. The deal is expected to help Grünenthal achieve its five-year goal of hitting €2bn in sales by 2022.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.